Drug Designing & Medicinal Drug Discovery

Invitation

It’s an immense honour and privilege for us to solicit your active participation in “29th International Conference on Drug Designing and Medicinal Drug Discovery” to be hosted in Toronto, Canada during September 27-28, 2019.

Medicinal Drug 2019 is designed to canvas recent research trends in all aspects of drug designing and drug discovery. This provides an excellent platform to all scientists, professors, subject experts, drug chemists, pharmaceutical engineers, research fellows, scientific communities, business professionals, students and executives around the globe to manifest their newest research discoveries, techniques and develop new fruitful collaborations. The invited talks by eminent scientists and subject experts are expected to seed research zeal in young minds and generate interest in them to take up the challenges of current research and flourish with magnificent research outcomes.

Those wishing to give presentations, can take up any scientific track out of enormous drug designing & drug discovery world ranging from theoretical aspects of drugs to advanced research in any allied area including drug discovery-synthesis, up to the minute. Everyone can avail this opportunity by submitting abstracts and getting registered for the conference.

We wish all the attendees worthwhile experience of sharing and exchanging their expertise with maestros from all over the world. Other conference offerings to look forward to are cultural exchanges and networking opportunities that await all the distinguished participants as they step into great city Toronto.

We fondly anticipate your presence in Toronto, at Medicinal Drug 2019

We really appreciate your time here!

Technical Sessions

Market Report

Market Value of fostering advances in Drug Designing & Drug Discovery: -

Drug Designing is a process of identifying incipient medicines for clinical conditions. There has been an ever incrementing desideratum for discovering incipient drug candidates due to the prevalence of several life-threatening diseases. Drug revelation technologies significantly contribute to the magnification of pharmaceutical industries. The major factors driving the magnification of the drug revelation market include a high prevalence of health disorders such as genetic disorders, nervous system disorders, diabetes, cardiovascular diseases and others; elevating demand for novel drug revelation technologies owing to the growing population; and advancements in the field of biotechnology, molecular biology and genomics. In addition, populated pipeline of novel drugs, coupled with patent expiry of several other drugs and incremented expenditure on health care are withal driving the market magnification. However, voluminous investments, shift of market branded drugs to generic drugs and delayed processing of regime regulations are obstructing the market magnification.

The drug discovery and drug designing market is segmented on the substructure of technology, services, end-users and geography. On the substructure of technology, the market is segmented into QPCR, DNA microarrays, protein microarrays, high-throughput screening, mass spectrometry, gel electrophoresis, chromatography, protein & nucleic acid isolation and other technologies. Predicated on accommodations, the market is segmented into Drug Metabolism and Pharmacokinetics (DMPK) accommodations, pharmaceutical, chemical and biological accommodations. The terminus-users of the drug revelation market include research institutes, biotech companies, and pharmaceutical companies, among others.

Ecumenical fine chemicals market is expected to witness a steady magnification during the forecast period, this magnification of ecumenical fine chemicals market is expected to be driven by magnification of the major end use industries. Pharmaceuticals and agrochemicals, being major consumers of fine chemicals, the magnification in these industries is in turn expected to fuel the magnification of ecumenical fine chemicals market during the forecast period. Moreover, growing demand from developing countries, especially those in Asia Pacific, is expected to result in magnification of ecumenical fine chemicals market. A major trend witnessed in ecumenical fine chemicals market is that the companies engendering fine chemicals are channelizing efforts towards development of efficient processes and more incipient products in order to gain a competitive advantage which eventually translates into a higher share in ecumenical fine chemicals market.

Market Growth and Research in the last and upcoming ten years:

The ecumenical market for drug revelation technologies reached proximately $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual magnification rate (CAGR) of 11.3% to proximately $79.5 billion for the period 2014-2021.

Funds allotted to Drug related Companies: -

The world’s 50 most sizably voluminous chemical corporations control an ecumenical market valued at $697 billion in 2009. At long last, industry (from little incipient businesses to prodigious ecumenical partnerships) gives a paramount part of the rest of, which give both to graduate research assistantships and support for students leading exploration on a venture.

Apart from the industrial personnel where most of the research work is done, other research communities include:-

• Academicians include Student community.
• Researchers include Post docs, Research Associates.
• Scientists include Professors, Associate Professors, and Assistant Professors.
• Industries include Presidents, CEO’s, and R&D Managers

Predicated on geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The market is further segmented, geographically, by the countries in the respective regions.

Major Associations and Societies:

Past Conference Report

MedChem and TDD 2017, USA

Past Reports  Gallery  

MedChem and Rational Drugs 2018

Past Reports  Gallery